Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
A phase 1/2 trial of Pembrolizumab, Ipilimumab and Nivolumab in advanced solid tumours, run by ModernaTX, Inc., now recruiting.
Overview
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05533697 by ModernaTX, Inc., with 361 participants planned, started 2022-09-01 and due to reach its primary completion in 2032-02-18. Interventions recorded: mRNA-4359, Pembrolizumab, Ipilimumab and Nivolumab.
Similar pages
not linked directly; found by shared links- TrialStudy BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of YL242 in Subjects With Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialN-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
Shares Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Shares Ipilimumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Shares Nivolumab, Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.